Vitamin K is the antidote for warfarin.
Idarucizumab is the antidote for dabigatran.
Protamine sulfate is the antidote for heparin.

Understanding Direct Oral Anticoagulants

Direct oral anticoagulants (DOACs) are medications used for various indications such as preventing stroke in non-valvular atrial fibrillation, preventing venous thromboembolism (VTE) after hip or knee surgery, and treating deep vein thrombosis (DVT) and pulmonary embolism (PE). To be prescribed DOACs for stroke prevention in non-valvular AF, certain risk factors must be present, such as prior stroke or transient ischaemic attack, age 75 years or older, hypertension, diabetes mellitus, or heart failure.

There are four DOACs available, namely dabigatran, rivaroxaban, apixaban, and edoxaban, which differ in their mechanism of action and excretion. Dabigatran is a direct thrombin inhibitor, while rivaroxaban, apixaban, and edoxaban are direct factor Xa inhibitors. The majority of dabigatran is excreted through the kidneys, while rivaroxaban is metabolized in the liver, and apixaban and edoxaban are excreted through the feces.

In terms of reversal agents, idarucizumab is available for dabigatran, while andexanet alfa is available for rivaroxaban and apixaban. However, there is currently no authorized reversal agent for edoxaban, although andexanet alfa has been studied. Understanding the differences between DOACs is important for healthcare professionals to make informed decisions when prescribing these medications.

Tinnitus could be an early indication of an aspirin overdose, as salicylate toxicity can cause respiratory alkalosis and subsequently metabolic acidosis within a few hours. The patient’s symptoms suggest the former, and the presence of tinnitus further supports this diagnosis.

Salicylate overdose can result in a combination of respiratory alkalosis and metabolic acidosis. The initial effect of salicylates is to stimulate the respiratory center, leading to hyperventilation and respiratory alkalosis. However, as the overdose progresses, the direct acid effects of salicylates, combined with acute renal failure, can cause metabolic acidosis. In children, metabolic acidosis tends to be more prominent. Other symptoms of salicylate overdose include tinnitus, lethargy, sweating, pyrexia, nausea/vomiting, hyperglycemia and hypoglycemia, seizures, and coma.

The treatment for salicylate overdose involves general measures such as airway, breathing, and circulation support, as well as administering activated charcoal. Urinary alkalinization with intravenous sodium bicarbonate can help eliminate aspirin in the urine. In severe cases, hemodialysis may be necessary. Indications for hemodialysis include a serum concentration of salicylates greater than 700mg/L, metabolic acidosis that is resistant to treatment, acute renal failure, pulmonary edema, seizures, and coma.

It is important to note that salicylates can cause the uncoupling of oxidative phosphorylation, which leads to decreased adenosine triphosphate production, increased oxygen consumption, and increased carbon dioxide and heat production. Therefore, prompt and appropriate treatment is crucial in managing salicylate overdose.

The enzyme CYP3A4, which belongs to the cytochrome P450 family, is strongly inhibited by grapefruit juice.

Statins are drugs that inhibit the action of an enzyme called HMG-CoA reductase, which is responsible for producing cholesterol in the liver. However, they can cause some adverse effects such as myopathy, which includes muscle pain, weakness, and damage, and liver impairment. Myopathy is more common in lipophilic statins than in hydrophilic ones. Statins may also increase the risk of intracerebral hemorrhage in patients who have had a stroke before. Therefore, they should be avoided in these patients. Statins should not be taken during pregnancy and should be stopped if the patient is taking macrolides.

Statins are recommended for people with established cardiovascular disease, those with a 10-year cardiovascular risk of 10% or more, and patients with type 2 diabetes mellitus. Patients with type 1 diabetes mellitus who were diagnosed more than 10 years ago, are over 40 years old, or have established nephropathy should also take statins. It is recommended to take statins at night as this is when cholesterol synthesis takes place. Atorvastatin 20mg is recommended for primary prevention, and the dose should be increased if non-HDL has not reduced for 40% or more. Atorvastatin 80 mg is recommended for secondary prevention. The graphic shows the different types of statins available.

The administration of metoclopramide can result in extrapyramidal side effects, with acute dystonia being the earliest and most common. This can lead to oculogyric crises, particularly in young individuals. Long-term side effects may include akathisia, parkinsonism, and tardive dyskinesia. The patient’s history does not suggest an allergic reaction, as there were no symptoms such as facial or lip swelling, breathing or circulatory issues, or the presence of a rash.

Metoclopramide is a medication that is commonly used to manage nausea. It works by blocking D2 receptors in the chemoreceptor trigger zone, which helps to alleviate feelings of sickness. In addition to its antiemetic properties, metoclopramide also has other uses, such as treating gastro-oesophageal reflux disease and gastroparesis caused by diabetic neuropathy. It is often combined with analgesics to treat migraines, which can cause gastroparesis and slow the absorption of pain medication.

However, metoclopramide can have some adverse effects, such as extrapyramidal effects, acute dystonia, diarrhoea, hyperprolactinaemia, tardive dyskinesia, and parkinsonism. These side effects are particularly problematic in children and young adults. It is important to note that metoclopramide should not be used in cases of bowel obstruction, but it may be helpful in cases of paralytic ileus.

Although metoclopramide primarily works as a D2 receptor antagonist, its mechanism of action is quite complex. It also acts as a mixed 5-HT3 receptor antagonist and 5-HT4 receptor agonist. The antiemetic effects of metoclopramide are due to its D2 receptor antagonist activity in the chemoreceptor trigger zone, while its gastroprokinetic effects are mediated by both D2 receptor antagonist and 5-HT4 receptor agonist activity. At higher doses, the 5-HT3 receptor antagonist activity also comes into play.

Muscle Effects of Common Medications

Many medications can have effects on muscles, including statins, metoclopramide, amitriptyline, cyclizine, and venlafaxine. Statins can increase the risk of muscle toxicity, especially in patients with a history of muscular disorders, high alcohol intake, renal impairment, or hypothyroidism. Metoclopramide is associated with extrapyramidal symptoms and acute dystonic reactions, but not generalised myositis. Amitriptyline and cyclizine are rarely associated with extrapyramidal symptoms and tremor, and amitriptyline may cause myalgia on drug withdrawal. Venlafaxine commonly causes hypertonia and tremor, and more rarely myoclonus, but not generalised myositis. It is important to be aware of these potential muscle effects when prescribing and monitoring these medications.

Muscle Effects of Commonly Prescribed Medications

Understanding Corticosteroids and Their Side-Effects

Corticosteroids are commonly prescribed therapies used to replace or augment the natural activity of endogenous steroids. They can be administered systemically or locally, depending on the condition being treated. However, the usage of corticosteroids is limited due to their numerous side-effects, which are more common with prolonged and systemic therapy.

Glucocorticoid side-effects include impaired glucose regulation, increased appetite and weight gain, hirsutism, hyperlipidaemia, Cushing’s syndrome, moon face, buffalo hump, striae, osteoporosis, proximal myopathy, avascular necrosis of the femoral head, immunosuppression, increased susceptibility to severe infection, reactivation of tuberculosis, insomnia, mania, depression, psychosis, peptic ulceration, acute pancreatitis, glaucoma, cataracts, suppression of growth in children, intracranial hypertension, and neutrophilia.

On the other hand, mineralocorticoid side-effects include fluid retention and hypertension. It is important to note that patients on long-term steroids should have their doses doubled during intercurrent illness. Longer-term systemic corticosteroids suppress the natural production of endogenous steroids, so they should not be withdrawn abruptly as this may precipitate an Addisonian crisis. The British National Formulary suggests gradual withdrawal of systemic corticosteroids if patients have received more than 40mg prednisolone daily for more than one week, received more than three weeks of treatment, or recently received repeated courses.

Palliative care prescribing for pain is guided by NICE and SIGN guidelines. NICE recommends starting treatment with regular oral modified-release or immediate-release morphine, with immediate-release morphine for breakthrough pain. Laxatives should be prescribed for all patients initiating strong opioids, and antiemetics should be offered if nausea persists. Drowsiness is usually transient, but if it persists, the dose should be adjusted. SIGN advises that the breakthrough dose of morphine is one-sixth the daily dose, and all patients receiving opioids should be prescribed a laxative. Opioids should be used with caution in patients with chronic kidney disease, and oxycodone is preferred to morphine in patients with mild-moderate renal impairment. Metastatic bone pain may respond to strong opioids, bisphosphonates, or radiotherapy, and all patients should be considered for referral to a clinical oncologist for further treatment. When increasing the dose of opioids, the next dose should be increased by 30-50%. Conversion factors between opioids are also provided. Opioid side-effects are usually transient, such as nausea and drowsiness, but constipation can persist. In addition to strong opioids, bisphosphonates, and radiotherapy, denosumab may be used to treat metastatic bone pain.

Overall, the guidelines recommend starting with regular oral morphine and adjusting the dose as needed. Laxatives should be prescribed to prevent constipation, and antiemetics may be needed for nausea. Opioids should be used with caution in patients with chronic kidney disease, and oxycodone is preferred in patients with mild-moderate renal impairment. Metastatic bone pain may respond to strong opioids, bisphosphonates, or radiotherapy, and referral to a clinical oncologist should be considered. Conversion factors between opioids are provided, and the next dose should be increased by 30-50% when adjusting the dose. Opioid side-effects are usually transient, but constipation can persist. Denosumab may also be used to treat metastatic bone pain.

It is recommended to increase the dose of metformin gradually, with a minimum of one week between each increase.

Metformin is a medication commonly used to treat type 2 diabetes mellitus. It belongs to a class of drugs called biguanides and works by activating the AMP-activated protein kinase (AMPK), which increases insulin sensitivity and reduces hepatic gluconeogenesis. Additionally, it may decrease the absorption of carbohydrates in the gastrointestinal tract. Unlike other diabetes medications, such as sulphonylureas, metformin does not cause hypoglycemia or weight gain, making it a first-line treatment option, especially for overweight patients. It is also used to treat polycystic ovarian syndrome and non-alcoholic fatty liver disease.

While metformin is generally well-tolerated, gastrointestinal side effects such as nausea, anorexia, and diarrhea are common and can be intolerable for some patients. Reduced absorption of vitamin B12 is also a potential side effect, although it rarely causes clinical problems. In rare cases, metformin can cause lactic acidosis, particularly in patients with severe liver disease or renal failure. However, it is important to note that lactic acidosis is now recognized as a rare side effect of metformin.

There are several contraindications to using metformin, including chronic kidney disease, recent myocardial infarction, sepsis, acute kidney injury, severe dehydration, and alcohol abuse. Additionally, metformin should be discontinued before and after procedures involving iodine-containing x-ray contrast media to reduce the risk of contrast nephropathy.

When starting metformin, it is important to titrate the dose slowly to reduce the incidence of gastrointestinal side effects. If patients experience intolerable side effects, modified-release metformin may be considered as an alternative.

Thyroid Management During Pregnancy: Considerations and Recommendations

Pregnancy can have a significant impact on thyroid function, and thyroid dysfunction can occur in many pregnant women due to pathological processes. Anti-thyroid drugs such as propylthiouracil and carbimazole can cross the placenta, potentially causing fetal goitre and hypothyroidism. It is recommended to keep the dose of these drugs as low as possible to maintain euthyroidism during pregnancy. Neonatal goitre and hypothyroidism can occur even with low-dose anti-thyroid drugs, and the neonatal goitre is permanent if it occurs.

Block-and-replace therapy with carbimazole and thyroxine is appropriate maternal management only in the treatment of isolated fetal hyperthyroidism caused by maternal TSH receptor antibody production in a mother who previously received ablative therapy for Graves’ disease. The neonatal goitre and hypothyroidism normalise in a few days’ time, and the confirmatory tests will come back normal even if the TSH is high on screening.

Specialist assessment is needed to differentiate between Graves’ hyperthyroidism and gestational hyperthyroidism. Women treated with anti-thyroid drugs may need to have the drug or dose amended by a specialist at the diagnosis of pregnancy, because these drugs cross the placenta. Women with current or previous Graves’ disease should have their TSH receptor antibody levels measured by the specialist. Carbimazole and propylthiouracil are present in breast milk, but this does not preclude breastfeeding as long as neonatal development is closely monitored and the lowest effective dose is used.

In summary, thyroid management during pregnancy requires careful consideration and monitoring to ensure the health of both the mother and the fetus.

Metoclopramide should be avoided in cases of bowel obstruction due to its prokinetic properties that can worsen the condition and even lead to perforation. Moclobemide, an antidepressant, may cause gastrointestinal upset but is not contraindicated in suspected bowel obstruction. Conservative management for bowel obstruction includes NG tube insertion, catheterization, and IV fluid resuscitation. Ondansetron, an antiemetic, can be useful in managing nausea. Opioid-based analgesia, such as pethidine and diamorphine, is effective in relieving obstruction-related pain despite its potential to reduce bowel motility. Intravenous fluids, such as Hartmann’s solution, are crucial in countering hypovolemia caused by fluid hypersecretion into the obstructed bowel lumen.

Metoclopramide is a medication that is commonly used to manage nausea. It works by blocking D2 receptors in the chemoreceptor trigger zone, which helps to alleviate feelings of sickness. In addition to its antiemetic properties, metoclopramide also has other uses, such as treating gastro-oesophageal reflux disease and gastroparesis caused by diabetic neuropathy. It is often combined with analgesics to treat migraines, which can cause gastroparesis and slow the absorption of pain medication.

However, metoclopramide can have some adverse effects, such as extrapyramidal effects, acute dystonia, diarrhoea, hyperprolactinaemia, tardive dyskinesia, and parkinsonism. These side effects are particularly problematic in children and young adults. It is important to note that metoclopramide should not be used in cases of bowel obstruction, but it may be helpful in cases of paralytic ileus.

Although metoclopramide primarily works as a D2 receptor antagonist, its mechanism of action is quite complex. It also acts as a mixed 5-HT3 receptor antagonist and 5-HT4 receptor agonist. The antiemetic effects of metoclopramide are due to its D2 receptor antagonist activity in the chemoreceptor trigger zone, while its gastroprokinetic effects are mediated by both D2 receptor antagonist and 5-HT4 receptor agonist activity. At higher doses, the 5-HT3 receptor antagonist activity also comes into play.